Literature DB >> 29094723

Liver cancer: Sensitizing hepatocellular carcinoma to oncolytic virus therapy.

Jennifer Altomonte1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29094723     DOI： 10.1038/nrgastro.2017.153

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  8 in total

1.  Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death.

Authors:  Douglas J Mahoney; Charles Lefebvre; Kristina Allan; Jan Brun; Cina A Sanaei; Stephen Baird; Nelson Pearce; Susanna Grönberg; Brian Wilson; Mikael Prakesh; Ahmed Aman; Methvin Isaac; Ahmed Mamai; David Uehling; Rima Al-Awar; Theresa Falls; Tommy Alain; David F Stojdl
Journal:  Cancer Cell       Date:  2011-10-18       Impact factor: 31.743

2.  Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma.

Authors:  Haipeng Zhang; Kai Li; Yuan Lin; Fan Xing; Xiao Xiao; Jing Cai; Wenbo Zhu; Jiankai Liang; Yaqian Tan; Liwu Fu; Fang Wang; Wei Yin; Bingzheng Lu; Pengxin Qiu; Xingwen Su; Shoufang Gong; Xuetao Bai; Jun Hu; Guangmei Yan
Journal:  Sci Transl Med       Date:  2017-08-23       Impact factor: 17.956

3.  Activation of Cyclic Adenosine Monophosphate Pathway Increases the Sensitivity of Cancer Cells to the Oncolytic Virus M1.

Authors:  Kai Li; Haipeng Zhang; Jianguang Qiu; Yuan Lin; Jiankai Liang; Xiao Xiao; Liwu Fu; Fang Wang; Jing Cai; Yaqian Tan; Wenbo Zhu; Wei Yin; Bingzheng Lu; Fan Xing; Lipeng Tang; Min Yan; Jialuo Mai; Yuan Li; Wenli Chen; Pengxin Qiu; Xingwen Su; Guangping Gao; Phillip W L Tai; Jun Hu; Guangmei Yan
Journal:  Mol Ther       Date:  2015-09-16       Impact factor: 11.454

Review 4.  New viruses for cancer therapy: meeting clinical needs.

Authors:  Tanner S Miest; Roberto Cattaneo
Journal:  Nat Rev Microbiol       Date:  2013-12-02       Impact factor: 60.633

5.  Hepatitis C virus suppresses the IRE1-XBP1 pathway of the unfolded protein response.

Authors:  Keith D Tardif; Kazutoshi Mori; Randal J Kaufman; Aleem Siddiqui
Journal:  J Biol Chem       Date:  2004-02-11       Impact factor: 5.157

6.  Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083).

Authors:  Han-Jie Zhou; Jinhai Wang; Bing Yao; Steve Wong; Stevan Djakovic; Brajesh Kumar; Julie Rice; Eduardo Valle; Ferdie Soriano; Mary-Kamala Menon; Antonett Madriaga; Szerenke Kiss von Soly; Abhinav Kumar; Francesco Parlati; F Michael Yakes; Laura Shawver; Ronan Le Moigne; Daniel J Anderson; Mark Rolfe; David Wustrow
Journal:  J Med Chem       Date:  2015-12-04       Impact factor: 7.446

7.  Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers.

Authors:  Yuan Lin; Haipeng Zhang; Jiankai Liang; Kai Li; Wenbo Zhu; Liwu Fu; Fang Wang; Xiaoke Zheng; Huijuan Shi; Sihan Wu; Xiao Xiao; Lijun Chen; Lipeng Tang; Min Yan; Xiaoxiao Yang; Yaqian Tan; Pengxin Qiu; Yijun Huang; Wei Yin; Xinwen Su; Haiyan Hu; Jun Hu; Guangmei Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-06       Impact factor: 11.205

Review 8.  Oncolytic virotherapy.

Authors:  Stephen J Russell; Kah-Whye Peng; John C Bell
Journal:  Nat Biotechnol       Date:  2012-07-10       Impact factor: 54.908
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.